Introduction
Members of the Myc oncoprotein family, which includes c-Myc, N-Myc, and L-Myc, are frequently deregulated in human cancers (Nesbit et al., 1999) . In addition to their transforming properties, these proteins may contribute to the neoplastic phenotype by inhibiting differentiation, reducing growth factor requirements, inducing genomic instability, and promoting angiogenesis (Prochownik and Kukowska, 1986; Stern et al., 1986; Dang, 1999; Yin et al., 1999a; Brandvold et al., 2000; Oster et al., 2002) . Myc proteins are basic helixloop-helix-leucine zipper (bHLH-ZIP) transcription factors whose known biological activities require that they heterodimerize with the bHLH-ZIP protein Max (Lu¨scher and Larsson, 1999) . Mostly as a result of DNA microarray analyses, a large number of positive and negative transcriptional targets for c-Myc have now been identified (see www.myc-cancer-gene.org). Many of these encode proteins that participate in cell growth and metabolism, apoptosis, and extracellular matrix formation, and a number of these are also transforming in their own right (Dang, 1999; Oster et al., 2002) . Such functional redundancy suggests that therapies based on the specific inhibition of individual Myc target gene products may be difficult to attain. Rather the specific inhibition of c-Myc itself may be a more viable alternative.
Previous attempts to inhibit c-Myc function have utilized approaches such as antisense oligonucleotides or gene transfer of Mad family member proteins (Holt et al., 1988; Chen et al., 1995; Wechsler et al., 1997) , which are HLH-ZIP partners of Max that negatively regulate c-Myc Baudino and Cleveland, 2001 ). These approaches have had some limited experimental success, but suffer from both theoretical and practical limitations.
In the current report, we have employed a yeast twohybrid-based approach (Bai and Elledge, 1996) as a simple, rapid, efficient, and quantitative way of screening for low-molecular-weight compounds that inhibit the association between c-Myc and Max. Similar assays have also allowed an evaluation of the specificity of these compounds against a wide range of heterodimeric transcription factors bearing bHLH, bZIP, or bHLH-ZIP dimerization domains similar to those found in cMyc and Max. Surprisingly, compounds identified in this way demonstrate remarkable specificity against cMyc-Max, function effectively in mammalian cells, and are able to inhibit the growth of c-Myc-overexpressing cells both in vitro and in vivo.
Results

Identification of c-Myc-Max-specific compounds by yeast two-hybrid screening
We employed a yeast two-hybrid-based approach (Bai and Elledge, 1996) in which the HLH-ZIP domains of c-Myc and Max were fused to the DNA-binding domain (BD) and transcriptional activation domain (AD), respectively, of the yeast Gal4 transcription factor (Langlands et al., 1997; Yin et al., 1999a) . The association between c-Myc and Max results in the de facto reconstitution of a fully functional transcriptional activator. A b-galactosidase gene containing a Gal4-binding site in its promoter and residing within the yeast genome, is induced upon the binding of c-Myc-Max, thus providing a simple, rapid, and quantitative readout of the proteins' dimerization status. Compounds that disrupt this association should therefore prevent induction of the enzyme. To control for nonspecific effects, a second yeast strain was created in which BD and AD fusions with the HLH proteins Id2 and E47, respectively, were expressed. We have previously shown that the interaction between these proteins can also be accurately and quantitatively assessed (Langlands et al., 1997) .
Each of the above yeast strains (hereafter referred to as Myc-Max and Id2-E47) was used to screen a chemical library of 10 000 low-molecular-weight compounds. Seven were identified that markedly inhibited bgalactosidase activity in Myc-Max yeast but not in Id2-E47 yeast (Figure 1) . Similarly, 10 compounds were identified that selectively inhibited enzyme activity in Id2-E47 yeast but not in Myc-Max yeast, and 28 dual specific compounds were identified that inhibited enzyme activity in both yeast strains. A determination of IC 50 's for all Myc-Max and Id2-E47 compounds, each performed in triplicate, indicated a range of 0.8-7 mm.
Specificity of Myc-Max compounds and their effects on Myc-Max heterodimers
To assess further the inhibitory profiles of the above compounds, we created 32 additional yeast strains expressing various interacting pairs of HLH-, ZIP-, or HLH-ZIP-containing proteins fused to the above Gal4 domains (Langlands et al., 1997; Yin et al., 1999a ). This multiplex system was then used to test each of the MycMax-and Id2-E47-specific compounds, and 11 of the dual-specific compounds for their abilities to inhibit bgalactosidase activity in each strain. As seen in Figure 2 , both the Myc-Max and Id2-E47 compounds demonstrated remarkable specificities for their originally identified targets. Thus, of the 231 possible combinations of Myc-Max-specific compounds with yeast expressing other protein pairs, only seven (3%) produced marked b-galactosidase inhibition, and of these, three involved the interaction between Max and a Mad family protein member. A similar degree of specificity was seen with the Id2-E47-specific compounds where, of the 330 other possible yeast þ compound combinations, only nine (2.7%), resulted in a comparable degree of enzyme inhibition. As expected of the dual-specific compounds, somewhat greater promiscuity was observed, with 34 of the 320 possible combinations (10.6%) producing marked b-galactosidase inhibition. However, these too were biased towards interactions involving other members of the Myc network. This analysis excluded compound 10039-D8, which inhibited b-galactosidase activity in every yeast strain tested and likely represents a nonspecific effect due, for example, to inhibition of DNA binding, Gal4-transcriptional activation, or b-galactosidase itself.
To determine whether the Myc-Max-specific compounds were acting directly on the heterodimer, we Myc-Max and Id2-E47 yeast were grown in the presence of each compound for approximately 18 h before performing b-galactosidase assays. Compounds inhibiting enzyme activity 475% compared to controls are indicated. Dual-specific compounds were then retested at 2-4-fold lower concentrations to uncover any previously unrecognized specificities. Under these conditions, four additional compounds, all selective for Id2-E47, were identified. Further evaluation of all the Myc-Max and Id2-E47 compounds, each performed in triplicate, indicated IC 50 's in the range of 0.8-7 mm. (b) Examples of selective b-galactosidase inhibition by MycMax-specific, Id2-E47-specific, and dual-specific compounds. Myc-Max and Id2-E47 yeast were grown in the presence of various low-molecular-weight compounds. In the upper set of panels, arrows indicate two compounds that inhibited enzyme activity only in Myc-Max yeast. In the lower set of panels, the arrow in the upper right indicates a compound that selectively inhibited enzyme activity in the Id2-E47 yeast, whereas the center arrow indicates a dual-specific compound. Note that active bgalactosidase registers as a reddish-brown color using the CNPG substrate, whereas its inhibition produces a yellow color (Prochownik and Van Antwerp, 1993) and asked whether any of the Myc-Max-specific compounds could prevent its association with a recombinant glutathione-S-transferase (GST)-Max fusion protein.
As seen in Figure 3 , each of the seven Myc-Max-specific drugs inhibited this association. No inhibition was seen with any of several Id2-E47-specific compounds or with compounds that failed to inhibit enzyme activity in any of the yeast strains ( Figure 3 and unpublished observations).
Inhibition of mammalian cell growth by Myc-Maxspecific compounds
Since c-Myc is necessary for the proliferation of mammalian cells (Prochownik et al., 1988; deAlboran et al., 2001) , we next determined whether the MycMax-specific compounds could inhibit this process. Control Rat1a fibroblasts (Rat1a-neo cells) or Rat1a cells transfected with a c-Myc expression vector (Rat1a-c-Myc cells; Yin et al., 1999b) were grown in the presence of each compound and viable cell counts were performed periodically thereafter. As seen in Figure 4a and b, all of the compounds strongly inhibited the growth of each cell line. During the initial 5-6 days, this was not accompanied by apoptotic cell death, with 490% of the cells remaining viable as determined by trypan blue staining and TUNEL assays (not shown). Longer periods of incubation, however, were accompanied by significant apoptosis in each case. These results are consistent with the idea that the compounds could inhibit c-Myc-Max interactions in mammalian cells even when c-Myc was deregulated and expressed at abnormally high levels. They are also consistent with previous findings that prolonged inhibition of c-Myc in some cases also leads to eventual apoptotic cell death (Kimura et al., 1995; Van Waardenburg et al., 1997; Ebinuma et al., 2001) .
As the proliferation of both Rat1a and Rat1a-c-Myc cells was inhibited by the compounds, it was not possible to ascribe this exclusively to the inhibition of c-Myc function. We therefore repeated the above experiments in a rat fibroblast cell line (TGR1) in which the c-Myc gene had been inactivated by homologous recombination (Matayek et al., 1997) . As seen in Figure 4c and d, each compound inhibited the growth of the parental cell line but had little or no effect on the growth of Myc À/À cells. Longer periods of incubation, performed so as to take into account the slower proliferative rate of these cells (Matayek et al., 1997) , still failed to result in any significant inhibition of growth rate (not shown).
Inhibition of c-Myc target gene expression and cell cycle progression by Myc-Max-specific compounds
A large number of both positively and negatively regulated c-Myc target genes has been identified to date, with many of these encoding proteins involved in cell cycle control, growth and metabolism, extracellular Figure 2 Multiplex analysis of inhibitory specificities. Yeast strains expressing the indicated combinations of BD and AD fusion proteins were grown as described (Langlands et al., 1997; Yin et al., 1999a) . Each compound was added at the concentration originally used to identify its specificity ( Figure 1 ). b-Galactosidase assays were performed at least three times. The degree of enzyme inhibition achieved with each compound is indicated in color: red: 475% inhibition; yellow: 25-75% inhibition; green: o25% inhibition Pharmacologic inhibitors of Myc-Max X Yin et al matrix formation, and apoptosis (Dang, 1999; Oster et al., 2002) . The ornithine decarboxylase (ODC) gene is a direct and positive c-Myc target that has been identified in independent microarray searches for cMyc-regulated genes (Bello-Fernandez et al., 1993; Coller et al., 2000; Guo et al 2000; O'Hagan et al., 2000) . Upregulation of ODC requires the obligate binding of c-Myc-Max heterodimers to two c-Mycbinding sites located within the first intron of the gene (Bello-Fernandez et al., 1993; Packham and Cleveland 1994) . Like c-Myc, ectopic overexpression of ODC is also transforming, proapoptotic, and promotes cell cycle progression (Bowlin et al., 1986; Auvinen et al., 1992; Packham and Cleveland, 1994) . We therefore asked whether any of the Myc-Max compounds could prevent the c-Myc-mediated induction of endogenous ODC. For these experiments, we utilized Rat1a cells harboring a cMyc-estrogen receptor fusion protein (MycERt) that exists in an inactive form in the absence of the estrogen analog 4-hydroxytamoxifen (4-HT) (Littlewood et al., 1995; Yin et al., 2001) . As seen in Figure 5a , the addition of 4-HT to Rat1a-MycER cells resulted in a nearly fivefold upregulation of ODC that was not significantly affected by the addition of DMSO vehicle alone. In contrast, each of the Myc-Max-specific compounds inhibited by 80-94% the ability of activated MycERt to upregulate ODC. Similar results were obtained with Rat1a-c-Myc cells (not shown).
In a more general test for the efficacy and specificity of each compound, we performed transient transfection (Matayek et al., 1997) were grown in the indicated concentrations of the Myc-Max-specific compounds or DMSO alone. Cell counts were performed at the indicated times (Zhang et al., 1997) . At 16 h after transfection, each of the Myc-Max compounds was then added to the cells for an additional 48 h. Cells were harvested and lysates were adjusted to take into account differences in b-galactosidase activity. Luciferase assays were then performed on the normalized samples as previousy described (Zhang et al., 1997; Yin et al., 1999a, b) . As seen in Figure 5b , each of the compounds significantly inhibited the c-Myc-Maxmediated induction of luciferase activity.
In control experiments, the same cells were transfected with MyoD and E12 expression vectors and a CAT reporter construct under the control of the MyoDresponsive muscle creatine kinase promoter (p3300-CAT; Van Antwerp et al., 1992) . As seen in Figure 5c , the concentrations of the compound that were effective in inhibiting c-Myc-Max-mediated transactivation in the previous two experiments had no effect on transactivation mediated by MyoD-E12. Together with the results shown in Figure 5a and b, these results extend those shown in Figure 3 to mammalian cells and demonstrate that the specificity for c-Myc-Max-induced targets is maintained.
In contrast to c-Myc's promotion of cell cycle progression, its inhibition halts this process and results in an accumulation of cells in G0/G1 (Freytag, 1988; Prochownik et al., 1988; deAlboran et al., 2001) . Therefore, we asked whether any of the above compounds could affect the cell cycle profiles of otherwise actively proliferating cells. Rat1a-c-Myc cells were plated at low concentrations and grown for 2 additional days until attaining approximately 30% confluency. The cells were then refed with fresh medium alone, medium containing DMSO only, or medium containing each of the Myc-Max-specific compounds. After 24 h, cells were harvested and cell cycle profiles were generated by flow cytometry following propidium iodide staining (Yin et al., 2001) . As seen in Table 1 , the addition of DMSO alone did not noticeably affect the cell cycle profiles. In contrast, all of the compounds tested caused significant increases in the fraction of the G0/G1 population. (Yin et al., 2001) were grown to approximately 75% confluency and then treated with 250 nm 4-HT in complete medium for 16 h. Where indicated, 4-HT and Myc-Max-specific compounds were added simultaneously at the concentrations shown in Figure 4 . Cells were harvested 16 h later after confirming that 495% of the cells remained viable. Equivalent amounts of protein (50 mg) were assayed for ODC as previously described (Zhang 1997; Nesbit et al., 2000) . The results show the average of triplicate determinations71 s.e. (b) C3H10T1/ 2 cells were transiently transfected with equal amounts of c-Myc and Max expression vectors together with the Myc-responsive 3Xmyc-E1b-luciferase reporter (lanes 2-10). After 16 h, later, each of the indicated compounds was added at the concentrations indicated in Figure 4 for an additional 48 h at which time cell lysates were prepared and assayed for b-galactosidase and luciferase. In the first lane, empty pSVL parental vector was substituted for the Myc and Max expression plasmids. The results show the average of triplicate determinations71 s.e. (c) C3H10T1/ 2 cells were transiently transfected with equal amounts of MyoD and E12 expression vectors together with the MyoD-responsive p3300MCK-CAT reporter (Van Antwerp et al., 1992) (lanes 2-10). After 16 h, later, each of the indicated compounds was added as described above. Cell lysates were prepared 48 h later and assayed for b-galactosidase and CAT in triplicate. In the first lane, empty pRcCMV vector was substituted for the MyoD and E12 expression vectors
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Taken together, the above experiments indicate that each of the Myc-Max-specific compounds is able to inhibit specifically the induction of defined c-Myc target genes as well as other presumed c-Myc targets whose products promote cell cycle progression.
Inhibition of tumorigenicity by Myc-Max-specific compounds
Rat1a-c-Myc cells form rapidly growing tumors in nude mice (Yin et al., 1999b ). Therefore, we tested four of the Myc-Max-specific compounds to determine whether, as suggested by the in vitro experiments depicted in Figure 4 , they could also inhibit in vivo tumor growth as well (Figure 6 ). Rat1a-c-Myc cells were therefore exposed to the indicated Myc-Max-specific compounds for 3 days at the concentrations shown in Figure 4 . Trypan Blue determinations of viability and TUNEL assays performed at the end of this period showed that 490% of the cells in each cell line remained alive. These cells were then inoculated into nude mice and monitored for tumor formation. Rat1a-c-Myc cells that had been incubated for 3 days in DMSO vehicle only served as a positive control. As seen in Figure 5 , all four compounds significantly reduced tumor growth.
Discussion
The results presented here demonstrate the utility of the yeast two-hybrid system for identifying selective lowmolecular-weight inhibitors of c-Myc, a bHLH-ZIP oncoprotein that is often deregulated in human cancer (Nesbit et al., 1999) . Since the frequency with which these compounds inhibit c-Myc function in mammalian cells is quite high, yeast-based approaches may be of more general utility in predicting potentially useful chemotherapeutic agents.
All of the compounds identified here appear to act directly by preventing or destabilizing the c-Myc-Max heterodimer (Figure 3) . While it might initially seem surprising that such simple molecules could affect protein-protein associations that occur over relatively large interfaces, single amino-acid substitutions in the HLH and ZIP domains of c-Myc and other proteins have long been known to prevent such associations, to alter their DNA-binding specificity, and to inhibit their biological function (Turner and Tjian, 1989; Smith et al., 1990; Van Antwerp et al., 1992; Bengal et al., 1994) . More recently, small molecules have been shown to prevent interactions between members of the Bcl-2 oncoprotein family that inhibit selective p53 functions, such as transcriptional activation and apoptosis, and that promote the reversion of p53 from a mutant to a wild-type conformation (Komarov et al., 1999; Foster et al., 1999; Wang et al., 2000) . That each of the molecules identified in our screen shows a signature inhibitory profile for the various HLH and HLH-ZIP interactions tested (Figure 2 ) further suggests that they may interact with different regions of these domains. Rat1a-c-Myc cells were grown for 2 days to approximately 30% confluency at which time fresh medium containing the indicated compounds was added. The concentration of each compound was as indicated in the legend to Figure 4 . After 24 h, later, cells were harvested and cell cycle parameters were determined on propidium iodide-stained nuclei as previously determined (Yin et al., 2001) . Numbers shown represent the averages of triplicate samples. Standard errors ranged from 2.2-6.7%. In all cases, the proportion of apoptotic cells (with subdiploid DNA) content was o5%, thus confirming the results of trypan blue staining. This raises the possibility that enhanced antitumor efficacy might be achieved with combinations of compounds. The recent report that transient reductions in c-Myc can produce in vivo tumor regression (Jain et al., 2002) is consistent with the data presented here (Figure 4) , and supports the idea that even short-term pharmacologic inhibition of Myc oncoproteins is an attractive therapeutic strategy. Structural analogs might also provide more potent alternatives than those reported here, which are effective in the low micromolar range. While this work was in progress, Berg et al. (2002) reported results similar to ours. The assay, however, utilized an in vitro-based system in which loss of fluorescence resonance energy transfer between green fluorescent protein-tagged c-Myc and Max was used as a way of assessing the ability of small molecules to disrupt the heterodimer. Like ours, the compounds identified by these investigators were also effective in the low micromolar range. However, differences in the biological activities of some of these compounds were seen in that they did not inhibit colony formation by transformed cells expressing endogenous levels of c-Myc. Since these cells overexpressed other oncogenes, however, it is possible that they were less dependent upon endogenous c-Myc for their growth than were the untransformed Rat11a fibroblasts used in the current study. Nonetheless, both these studies provide independent support for the idea that lowmolecular-weight compounds can inhibit protein-protein interactions that normally occur over relatively large surfaces.
Finally, it should be noted that secondary outcome of our study was the identification of compounds that are quite specific for the Id2-E47 heterodimer (Figures 1  and 2 ). Id proteins serve as negative regulators of a variety of tissue-specific differentiation processes, may promote proliferation by virtue of their interaction with specific cell cycle regulators, and are overexpressed in some cancers (Hasskarl and Munger, 2002) . This suggests the possibility that molecules such as those identified here might be employed in a variety of settings and could conceivably be utilized in combination with Myc-Max compounds for certain cancer therapies.
Materials and methods
Yeast two-hybrid assays
Fusions between the Gal4 DNA-binding domain (BD) of cMyc and Id2 in the pGBT9 vector have been previously described, as have fusions between the Gal4 activation domain (AD) and Max and E47 in the pGAD vector (Langlands et al., 1997) . The construction and characterization of other BD and AD fusion partners have also been previously described (Langlands et al., 1997; Yin et al., 1999a) . Each consisted of at least the minimal HLH, ZIP, or HLH-ZIP domain that had been amplified from various parental vectors using the polymerase chain reaction. All primers were prepared with EcoRI and BamHI or BglII restriction sites to allow for directional cloning of the products into the pGBT9 BD or pGAD424 AD vectors. Each individual plasmid was first tested to ensure that it did not self-transactivate the b-galactosidase reporter when expressed in the Y153 yeast strain (not shown). To perform quantitative assays, each yeast strain was grown overnight at 301C standard SC medium lacking leucine and tryptophan. The cultures were diluted in the same medium to an OD 600 of 0.15 and 50 ml were inoculated into 96-well plates using a Biomek 2000 Laboratory Automated Workstation (Beckman-Coulter, Brea, CA, USA) just prior to the addition of compounds.
Low-molecular-weight compound library screening
The DIVERSet combinatorial library (Chembridge, Inc. San Diego, CA, USA) consists of 10 000 drug-like small molecules (average molecular weight ¼ 350 Da), which were selected based on 3D pharmacophore analysis to cover the broadest part of biologically relevant pharmacophore diversity space. Each compound was dissolved in DMSO at an average concentration of 14 mm. A stock solution (0.5 ml) of each compound was added to triplicate wells of yeast and incubated at 301C with constant agitation for approximately 18 h until the yeast had reached saturation densities. The average final concentration of each compound was 10 mm. The OD 600 of each well was determined on a SpectraMax Plus automated plate reader (Molecular Devices, Sunnyvale, CA, USA) and compared to the ODs of control wells that had been inoculated with DMSO only. Under these conditions, DMSO had no effect on the growth of yeast and none of the compounds inhibited growth by 450%. b-Galactosidase assays were then performed overnight as previously described (Langlands et al., 1997; Yin et al., 1999a) using chlorophenol red-b-d-galactopyranoside (CPRG) (Roche Applied Science, Mannheim, Germany) as a substrate. ODs were determined at 580 nm, again using the automated plate reader. After normalizing for differences in densities of the yeast, the degree of bgalactosidase inhibition was ranked as minimal (o25%), moderate (25-75%), or marked (475%). Each determination was performed in triplicate and all compounds identified as giving marked inhibition were confirmed on multiple subsequent occasions. Compounds registering as positive were reassayed in triplicate in order to determine IC 50 's, and errors were generally o5%. Chemical identities for each of the MycMax-specific compounds were: #10009-G9: bicyclo[2.2.1]hept-2-yl-[2-(4-nitro-phenyl)-ethyl]-amine; #10031-B8: 1-[2,5-dioxo-1-(4-propoxy-phenyl)-pyrrolidin-3-yl]-piperidine-4-carboxylic acid; #10050-C10: 4-methyl-2-[N 0 -(6-methyl-2-phenyl-chroman-4-ylidene)-hydrazino]-thiazole-5-carboxylic acid (3-nitrophenyl)-amide; #10058-F4: 5-(4-ethyl-benzylidene)-2-thioxothiazolidin-4-one; #10074-A4: 3-[3-(3,6-dichloro-carbazol-9-yl)-2-hydroxy-propyl]-thiazolidine-2,4-dione; #10074-G5: biphenyl-2-yl-(7-nitro-benzo[1,2,5]oxadiazol-4-yl)-amine; #10075-G5: 1-(3-Chloro-phenyl)-3-diethylamino-pyrrolidine-2,5-dione.
GST pull-down experiments
A human c-Myc cDNA in the pBluescript SK þ vector (Stratagene, La Jolla, CA, USA), was transcribed and translated in vitro with T7 RNA polymerase using the TnT expression system (Promega, Madison, WI, USA) according to the directions of the supplier. The reaction was performed in the presence 20 mCi of [ 35 S]methionine (Perkin-Elmer, Boston, MA, USA, sp. act. 1175 Ci/mmol) at 321C for 90 min. Onetenth of the reaction was mixed on ice with 500 ng of recombinant, affinity-purified GST-Max protein in a total volume of 50 ml of dilution buffer (10% glycerol, 100 mm KCl; 10 mm Tris-HCl; 1 mm EDTA; 1 mm dithiothreitol) (Yin et al., 1999a) . In all, 1 ml of each compound, dissolved as a stock Pharmacologic inhibitors of Myc-Max X Yin et al solution in DMSO, was then added to give a final compound concentrations ranging from 5 to 50 mm. The complete reactions were incubated for 30 min at 401C to allow for dimerization between the two proteins. At the end of the incubation, 1 ml of binding buffer and 50 ml of washed glutathione-agarose beads (BioRad, Hercules, CA, USA) were added for 5 min with constant agitation. The beads were then pelleted by centrifugation, washed three times in binding buffer, and resuspended and boiled for 5 min in SDS-PAGE running buffer. The sample was resolved by SDS-PAGE on a 10% polyacrylamide gel, which was then dried and autoradiographed.
Mammalian cell culture and transfections
Rat1a-neo, Rat1a-c-Myc, Rat1a-MycER, and C3H10T1/2 cells have been previously described (Van Antwerp et al., 1992; Yin et al., 1999a, b) . TGR-1 fibroblasts and the derivative c-Myc 'knockout' (KO) cell line HO15.19 were also as described (Matayek et al., 1997; Yin et al., 1999b) . All cells were cultured in Dulbecco's modified minimal essential medium (D-MEM) supplemented with 10% fetal calf serum, 2 mm glutamine, and penicillin and streptomycin (all from Gibco-BRL, Grand Island, NY, USA). Rat1a-MycER and HO15.19 cells were also routinely maintained in 1 mg/ml puromycin (Sigma) and 200 mg/ml G-418 (Gibco-BRL), respectively. Transient transfections of the pSVL-c-Myc and pSVL-Max expression vectors (each at 2 mg/plate) and the 3 Â Myc-adenoE1b-luciferase reporter vector (1 mg/plate) in C3H10T1/2 cells were performed in 60 mm tissue culture plates as described (Zhang et al., 1997) . Transient transfections of pRcCMV-MyoD and pRcCMV-E12 (each at 2 mg/plate), and the p3300MCK-CAT reporter vector (1 mg/plate) in the same cells were also performed as described (Van Antwerp et al., 1992) . All transfections also contained 1 mg/plate to pCMV-bgalactosidase to control for transfection efficiencies). In all cases, luciferase and CAT assays were performed as previously described (Van Antwerp et al., 1992; Zhang et al., 1997) after normalizing for differences in b-galactosidase levels.
Ornithine decarboxylase and cell cycle assays
These were performed as previously described (Nesbit et al., 1998 (Nesbit et al., , 2000 Yin et al., 2001) . Cell cycle profiles were performed on propidium iodide-stained nuclei as previously described (Yin et al., 1999a ) using a Becton-Dickinson FACStar flow cytometer. A total of 2 Â 10 4 cells were analysed in triplicate for each point and quantitation was performed using single histogram statistics.
Cell growth and tumorigenicity assays
All growth curves were performed in 12-well tissue culture plates as previously described (Yin et al., 1999b) . Rat1a-neo, Rat1a-c-Myc, and TGR-1 fibroblasts were seeded at an initial density of 2 Â 10 3 cells/well whereas HO15.19 c-Myc KO cells were seeded at 5 Â 10 3 cells/well. The following day, each compound, or DMSO vehicle alone, was added to the indicated final concentrations. Fresh medium and compound were added every 3-4 days. Cells were trypsinized and manually counted at the indicated times. In all of the above cases, TUNEL assays performed 4-5 days after the addition of the compounds showed that fewer than 15% of the cells were undergoing apoptosis (not shown). For in vivo assays, Rat1a-cMyc cells were grown to approximately 50% confluency. Fresh medium plus the indicated compounds, or DMSO vehicle alone, were then added to cells for an additional 3 days. The final concentration of each compound was as indicated in Figure 4a and b. At the end of this time, none of the cultures contained fewer than 10% apoptotic cells as determined by trypan blue staining and TUNEL assays. The cells were then washed twice in PBS, trypsinized and resuspended in a minimal volume of fresh medium containing the same concentration of compound. In total, 2 Â 10 7 cells were then inoculated subcutaneously into the flanks of nude mice (five animals per group) and no additional compound was administered for the duration of the experiment. Tumor growth was monitored weekly and the average tumor volume (71 s.e.) was calculated as previously described (Yin et al., 2002) .
